Krishna Institute of Medical Sciences Limited (KIMS) — Announcement | 8 August 2026

· NSE Neutral
By StockFin Research Team AI-Assisted Analysis Source: BSE/NSE Filings
📢 Key Event
KIMS Hospitals reported robust Q1 FY27 growth with debt reduction via QIP and expansion into new regions.
🔄 What Changed
Revenue grew 36.1% YoY to INR 1,196 crore; EBITDA margin held at 20.1%; new hospital openings accelerated; debt reduced by INR 1,100 crore
🔮 What's Next
Target mid-teens EBITDA margins in Kerala this year, 20-22% long-term; achieve 70% occupancy in Telangana within 3-4 years; stabilize Electronic City facility by year-end; repay additional debt using internal cash flow
💡 Investor Takeaway
KIMS is executing a disciplined expansion while aggressively reducing debt, positioning for margin expansion and sustainable growth in core markets.

KIMS Hospitals reported a 36.1% YoY revenue jump to INR 1,196 crore in Q1 FY27, driven by strong volume growth and a successful INR 1,500 crore QIP to cut debt. New units in Kerala and Bengaluru are scaling rapidly, with EBITDA margins targeting mid-teens in Kerala and 20-22% long-term. Management highlighted execution focus on stabilizing new hospitals, managing receivables, and sustaining demand, while noting risks from government receivables and cost pressures.

📄 View Original Announcement (PDF)

About Krishna Institute of Medical Sciences Limited (KIMS)

Healthcare · Healthcare Services · Listed on NSE

Market Cap: ₹30,476.58 Cr P/E: 80.3

View full KIMS stock details →

📡 Get AI alerts when KIMS files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track KIMS — Free

📊 More KIMS filings

See all KIMS filings →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when KIMS files new disclosures

Track KIMS filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track KIMS — Free

Free account · 2 AI queries/day